MRI-based radiomics to predict pathology response after neoadjuvant therapy in head and neck cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will analyze MRI radiomics combined with clinical data to identify patterns associated with pathological complete response (pCR) after neoadjuvant treatment in locally advanced head and neck squamous cell carcinoma. Participants have two to three cycles of neoadjuvant therapy (chemotherapy plus a PD-1 inhibitor) and undergo MRI within 30 days before starting therapy, followed by radical surgery. The aim is to develop a model that predicts pCR to guide individualized treatment decisions. Data will include MR imaging and complete clinical information and will focus on correlating imaging features with surgical pathology outcomes. The study is conducted at Sun Yat-Sen Memorial Hospital in Guangzhou, China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* (a) patients pathologically diagnosed as head and neck squamous cell carcinoma;
* (b) patients receiving two or three courses of neoadjuvant therapy (traditional chemotherapy plus PD-1 inhibitor);
* (c) MR scan within 30 days before the first course of neoadjuvant therapy;
* (d) patients undergoing radical surgical dissection following neoadjuvant therapy;
* (e) complete clinical data available.

Exclusion Criteria:

* (a) previous head and neck treatment history;
* (b) obvious motion or metal artifacts on the MRI image;
* (c) distant metastasis;
* (d) concurrent malignancies.

Where it's running

• Sun Yat-sen Memorial Hospital
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Lin
• Email: linpliang3@mail.sysu.edu.cn
• Phone: 0086-020-34071439

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC

  This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07894458

• Adding tislelizumab with or without the probiotic Probio-M9 to pre-surgery chemoradiation for pMMR/MSS locally advanced rectal cancer.

  This will see if adding the PD-1 drug tislelizumab, with or without the probiotic Probio-M9, to standard pre-surgery chemoradiation helps adults with pMMR/MSS locally advanced rectal cancer.

  Recruiting Phase 2 Seventh Medical Center of PLA General Hospital · Beijing, Beijing Municipality · NCT07458529

• Ivonescimab in Neoadjuvant NSCLC: Testing a PD-1/VEGF Bi-specific

  This study tests Ivonescimab, a PD-1/VEGF bispecific antibody, in people with non-small cell lung cancer to see if it works better or has different safety than standard PD-1 inhibitors before surgery.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07359040

• Predicting Immunotherapy Response from Live Tumor Biopsies

  This project will try to see if analyzing live tumor biopsy samples kept in their 3D environment can predict whether people with advanced solid tumors will respond to immunotherapy.

  Recruiting at 7 sites Elephas · Fort Smith, Arkansas and 7 other locations · NCT07327489

• Multi-omics blood and CT monitoring for early detection of lung cancer recurrence after neoadjuvant therapy and surgery

  This project tests whether combining blood-based multi-omics (metabolomics and cfDNA), CT radiomics, and AI can noninvasively detect early recurrence after surgery in NSCLC patients treated with neoadjuvant immunotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07291921

• β-hydroxybutyrate with short-course radiotherapy, immunotherapy and CAPEOX before surgery for locally advanced rectal cancer

  This phase II trial will test whether adding β-hydroxybutyrate supplements to short-course radiotherapy followed by immunotherapy plus CAPEOX chemotherapy improves outcomes for people with locally advanced rectal cancer before surgery.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07239466

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.